Acumen pharmaceuticals to report fourth quarter and year-end 2024 financial results on march 27, 2025

Newton, mass., march 20, 2025 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, today announced that the company will report fourth quarter and year-end 2024 financial results on thursday, march 27, 2025. the company will host a conference call and live audio webcast at 8:00 a.m. et to provide a business and financial update.
ABOS Ratings Summary
ABOS Quant Ranking